PROLOR Biotech's hGH-CTP Phase I study data to be presented at the BIO CEO & Investor Conference

PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH ) today announced that final data from a randomized, dose-escalating Phase I clinical study of its longer-acting version of human growth hormone (hGH-CTP) will be featured in an oral presentation by PROLOR management at the 12th Annual BIO CEO & Investor Conference to be held at the Waldorf-Astoria Hotel in New York City on February 8-9, 2010.

The Phase I study was designed to assess the safety, tolerability, and pharmacokinetic and pharmacodynamic properties of hGH-CTP.  The presentation, which will also include an update on progress in other PROLOR programs, is scheduled at 3:00 PM EST on February 8, 2010.  To view a live webcast of the presentation, visit http://www.veracast.com/webcasts/bio/ceoinvestor2010/46112117.cfm.

The advisory committee of the BIO CEO & Investor Conference, comprised of leading institutional investors and industry analysts, selected PROLOR Biotech to present at the event, which is the largest independent investor conference focused on leading publicly traded biotech companies.